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Abstract: Asthma remains one of the most important challenges to pediatric public health in the US.  A 
large majority of children with persistent and chronic asthma demonstrate aeroallergen sensitization, 
which remains a pivotal risk factor associated with the development of persistent, progressive asthma 
throughout life.    In individuals with a tendency toward Type 2 inflammation, sensitization and exposure 
to high concentrations of offending allergens is associated with increased  risk for development of, and 
impairment from, asthma.   The cascade of biological responses to allergens is primarily mediated 
through IgE antibodies and their production is further stimulated by IgE responses to antigen exposure.  
In addition, circulating IgE impairs innate anti-viral immune responses. The latter effect could magnify 
the effects of another early life exposure associated with increased risk of the development of asthma – 
viral infections.  Omalizumab binds to circulating IgE and thus ablates antigen signaling through IgE-
related mechanisms.  Further, it has been shown restore IFN-α response to rhinovirus and to reduce 
asthma exacerbations during the viral season.   
We therefore hypothesized that early blockade of IgE and IgE mediated responses with 
omalizumab  would prevent the development and reduce the severity of asthma in those at high risk for 
developing asthma.  Herein, we describe a double-blind, placebo-controlled trial of omalizumab in 2-3 
year old children at high risk for development of asthma to prevent the development and reduce the 
severity of asthma.  We describe the rationale, methods, and lessons learned in implementing this 
potentially transformative trial aimed at prevention of asthma.  
 
Introduction:  
Asthma affects one out of 11 (7.1 million) U.S. children and is an incurable disease that degrades 
quality of life and may lead to significant, long term disability. A large majority of children with 
persistent and chronic asthma demonstrate aeroallergen sensitization (allergen-specific IgE antibody 
production), which remains a pivotal risk factor for developing persistent, progressive asthma 
throughout life[1, 2] .  Furthermore, wheezing with viral infections during the first several years of life 
amplifies this effect[2-4].  In high risk children, aeroallergen sensitization precedes viral wheezing and is 
associated with the persistence and progression of the disease[5].   Most aeroallergen sensitization 
begins around age 1-3 years and escalates during school age[6].  Those who develop early sensitization 
are at greatest risk for persistent asthma and severe exacerbations of their disease[7-9].    The 
progression appears to be dependent on exposures to offending allergens-- the greatest incidence and 
impairment from asthma is seen in those who are sensitized and exposed to high concentrations of 
offending allergens with varying and complex relationships[10] [11-15].  Avoidance strategies aimed at 
environmental allergens are complex, time-consuming and often incomplete. However, several multi-
faceted trials applying environmental exposure reduction in early life among at risk children have 
suggested long-term reduction in development and intensity of asthma [16-19] implicating that 
approaches to prevent allergic responses at a young age could potentially do more than control 
symptoms.   
In addition to its role in mediating allergen-induced responses, IgE signals impair innate anti-
viral immune responses[20, 21], which could lead to increased viral infections and thus potentially 
further enhance the cascade of progression to asthma.  In experimental settings, IgE antibodies not only 
trigger mast cell-mediated hypersensitivity reactions but also act to promote Type 2 (allergic) immune 
responses and suppress the production protective Treg responses[22, 23].  This early Type 2 polarization 
appears to prime children for asthma while augmenting susceptibility to viral induced lower respiratory 
infections, which can further induce the development of asthma. 
Omalizumab (Xolair®) is a recombinant humanized monoclonal anti-immunoglobulin E (anti-IgE) 
antibody that works by blocking IgE-mediated processes and is FDA approved for children ages 6 years 
and above with allergic and severe asthma.  It was shown in two NIAID funded asthma trials in inner-city 
children with asthma to markedly reduce asthma exacerbations in school aged children during the 
respiratory viral season[24, 25].   The Preventative Omalizumab or Step-up Therapy for Severe Fall 
Exacerbations (PROSE) trial showed that omalizumab treated children had restored anti-viral IFN-α 
response to rhinovirus (one of the most  common causes of viral wheezing in school age children)[4, 25].  
This suggests that omalizumab may prevent IgE driven responses to offending allergens and attenuate 
viral infections in those with Type 2 asthma.     We describe the design, methods, and lessons learned of 
the PARK trial which tests the hypothesis that blockade of IgE in young children (age 2-3) at high risk for 
development of asthma will prevent asthma.  
STUDY DESIGN AND METHODS:  
Study Design  
PARK is a 4 year  multi-center, double-blinded, randomized, parallel design, placebo-controlled trial of 
omalizumab (anti-IgE) in children age 2-3 years at high-risk for developing asthma. Subjects are treated 
with omalizumab or placebo for 2 years and then followed for an additional 2 years to assess the 
development of asthma.   
Study Population: 
Rationale for Study Population 
The proposed study population will be approximately 250 children aged 24 to 47 months of age at the 
time of screening who are at high risk for asthma.  Potential participants will be assessed for criteria that 
have been previously shown to correlate with subsequent persistent asthma in prospective studies of 
early childhood wheezing. The inclusion and exclusion criteria for this prevention study (see Table 1) 
were designed to strike a balance between indicating sufficient asthma risk  (2 or more wheezing 
episodes) such that 2 years of injectable medication in small children was ethically acceptable and not 
such frequent symptoms (>4 wheezing episodes)  that persistent asthma was already established. 
Table 1. Inclusion/Exclusion Criteria 
Inclusion Criteria Individuals who meet all of the following criteria are eligible for enrollment as 
study participants: 
1. Parent/guardian must be able to understand and provide signed and dated 
written informed consent; he/she must also be able to communicate with 
study staff 
2. Age range: 24 through 47  months of age at  the screening visit; participant 
must be under 4 years of age at the time of the randomization visit [exceptions 
for randomization of participants up to 48 months + 2 weeks may be allowed if 
an unforeseen situation occurs (e.g., lost samples, delays in IgE results, etc.)] 
3. 2 to 4 wheezing episodes in the past year documented on physical 
examination by a health care provider.  Wheezing events separated by at least 
5 consecutive days without wheezing shall be counted as separate episodes.   
4. Sensitization to one or more aeroallergens (by skin test wheal size at least 3 
mm greater than negative control or allergen specific IgE ≥ 0.35 kU/L) 
5. Diagnosis of asthma or allergy by a medical professional, or a positive test for 
allergy (skin test or serum test) in a first degree relative   
 
6. Parent-reported history of participant having had either clinical varicella or 
administration of varicella vaccine     
7.  If participating in food immunotherapy treatment that is not part of a clinical 
trial, has been on an established maintenance regimen implemented 
continuously for a minimum of 2 months                     
Exclusion Criteria Individuals who meet any of these criteria are not eligible for enrollment as study 
participants:  
1. >4 episodes of wheezing in the past year  
2. Use of Step 5 or Step 6 therapy (reference table 3) at the time of 
enrollment (Visit 0). (Previously use of inhaled steroids or inhaled steroids 
plus long acting beta agonists for respiratory symptoms for greater than  4 
months in the past year was exclusionary - Adaptation 3/2020 and 
explained in Discussion) 
3. Need for systemic corticosteroids or a hospitalization for respiratory 
symptoms within four weeks prior to screening 
4. Three or more courses of systemic corticosteroids for wheezing illnesses in 
the last year 
5. More than four days of symptoms of wheezing, or tightness in the chest or 
cough in the past two weeks causing at least minimal limitation of activity 
6. More than four days of albuterol treatment (for symptoms) in the past two 
weeks 
7. More than one night of symptoms of wheezing, chest tightness, or cough 
causing sleep disruption in the past two weeks 
8. More than one night of albuterol treatment (for symptoms) in the past 
two weeks 
9. Prematurity (<34 weeks gestation) 
10. Need for oxygen for more than 5 days in the neonatal period 
11. History of intubation or mechanical ventilation for respiratory illness 
12. Other significant medical conditions, including but not limited to major 
congenital anomalies,  cystic fibrosis, chronic pulmonary diseases, 
bronchopulmonary dysplasia, thoracic surgery, history of tuberculosis, 
immunodeficiency (primary or secondary), seizure disorders 
13. Expecting to relocate within 4 years of study initiation to a place which 
would make in-person clinical visits impossible 
14. Unable to adhere to study  
15. activities 
16. Prior aeroallergen immunotherapy or use of biologics including anti-IgE 
17. Prior IVIG or systemic immunosuppressant other than corticosteroids 
18. History of hypoxic seizures during a wheezing episode 
19. Total IgE outside of the omalizumab dosing range  
20. Enrolled in any other therapeutic interventional clinical trial within the 
past 30 days 
21. Platelet count < 150 x 109/L at the screening visit  
22. Past or current medical problems or findings from physical examination or 
laboratory testing that are not listed above, which, in the opinion of the 
investigator, may pose additional risks from participation in the study, may 
interfere with the participant’s ability to comply with study requirements 
or may impact the quality or interpretation of the data obtained from the 
study. 
23. History of severe anaphylactic/anaphylactoid reactions from any cause 
 
Exclusion criteria will be evaluated using 2-week recall If the participant meets any 
of the following criteria at any of the evaluations (screening, ICS step down run-in 
period or 4-week off ICS run-in period), then he/she is ineligible for randomization. 
1. More than four days of symptoms of wheezing, or tightness in the chest or 
cough  in the past two weeks causing at least minimal limitation of activity  
2. More than four days of albuterol treatment (for symptoms) in the past two 
weeks 
3. More than one night of symptoms of wheezing, or tightness in the chest or 
cough causing sleep disruption in the past two weeks 
4. More than one night of albuterol treatment (for symptoms) in the past 
two weeks 
5. Symptomatic to the point of requiring controller medication 
[prednisone/prednisolone per the detailed rescue algorithm in the 
protocol, or inhaled corticosteroids with or without long-acting beta-
agonists,  other systemic corticosteroids, formoterol, theophylline, 
cromolyn, leukotriene antagonists (for wheezing), or salmeterol prescribed 
outside of the protocol] during the run-in/washout period. For participants 
in the ICS step down run-in, an increase in ICS step above the current step 
or the addition of other controller medication will be exclusionary.  
6. Hospitalized for respiratory symptoms 
 
Patients may be re-enrolled into the run-in period if the subject fulfills all other 
inclusion/exclusion criteria and has not required hospitalization or systemic 
corticosteroids for four weeks prior to re-enrollment.  Participants who come off 
controller medications or have their ICS decreased in order to enroll in the study 





Enrolled participants enter a run-in period to characterize stability off asthma 
controllers and level of control at baseline prior to randomization. Those who 
exacerbate during the run-in period used to assess stability of respiratory 
symptoms to further evaluate eligibility for study participation. 
The length of the run-in and the schedule for respiratory symptom assessment 
depends on the medications a participant is taking and how long they have been 
taken at the time of the enrollment: 
 For participants not taking any controller medications at enrollment, and 
who have been stable for 2 weeks off controller medication, a single 
evaluation will occur after a 2-week run-in period (+1 week window).   
 Participants who are on ICS medication at a dose equivalent to Step 1 (as 
in Table 3) and/or are on a non-ICS controller medication (e.g., LTRA) at 
enrollment will enter a 4-week run-in period off all controllers. 
 Participants who have taken ICS medication at a dose equivalent to Steps 
2, 3 or 4 for more than 4 consecutive months at enrollment will decrease 
by one step at 2-week intervals until they reach Step 0 (no controllers).  A 
telephone contact will take place to assess stability before each dose 
reduction, and an in-clinic visit will occur before beginning the 4-week run-
in period without ICS. The participant will be assessed at enrollment for 
stable respiratory symptoms and, if stable, will start the run-in by 
decreasing their ICS one step (e.g., a child who was taking Step 2 ICS will 
begin the run-in on Step 1 ICS). (Adapted March 2020 when protocol 
amended to include children on > 4 months ICS) 
 Participants who have taken ICS medications at a dose equivalent to Steps 
2, 3, or 4 for less than or equal to 4 consecutive months at enrollment can 
be either stepped down as described above or have the medication 
discontinued at enrollment based on the judgment of the study clinician.  
 Once on Step 0 (no controllers), there will be two consecutive 2-week 
evaluations to confirm that the participant remained stable off ICS for a 
full 4-week period prior to randomization.   
 
Study Procedures  
Allergen Skin Testing:   Skin testing will be performed to cat, dog, mouse, oak, aspergillus, alternaria, 
German/American cockroach mix, D. farinae/D. pteronyssinus mix, timothy grass and a clinic-specific 
battery of locally relevant allergens (not to exceed 16 tests in total including the positive and negative 
controls) at the PARK clinical centers by certified personnel.  Participants will be asked to stop taking 
antihistamines for 5-7 days (dependent on the medication) prior to the visits at which the skin testing is 
performed to limit interference with the results of the skin test. 
Pulmonary Function Test (Full-volume spirometry):  Beginning at the week 80 visit, sites will begin 
teaching spirometry to participants.  All spirometry will be conducted using the Global Lungs Initiative 
equations for predicted normal values.  Pre- and Post- bronchodilator (4 puffs albuterol) spirometry will 
be conducted at Study Visits at weeks 92, 144 and 192.   
At sites with airway oscillometry testing systems available, oscillometry will be performed consistent 
with ATS/ERS guidelines for preschool testing.   
Venipuncture:   A venous blood sample will be obtained at the initial screen visit, two months after 
initiation of treatment and then annually and analyzed for safety labs and other mechanistic labs as 
shown in Table 2 Schedule of Events. 
Questionnaires: Respiratory questionnaire/history will be conducted in conjunction with monthly study 
visits during the treatment period and either via phone or clinic visits during the observation period 
using well validated surveys [24, 26, 27].  The same questionnaire scripts will be used by research clinic 
personnel during both visits and telephone interviews. Self-report accuracy will be enhanced by asking 
the parent/legal guardian to estimate medication use during the previous 1-week period. Two-week 
recall has been adopted for symptom assessment given the greater reliability of this interval compared 
to 1-month recall, based on the success of its use in the PEAK Trial[26] , the National Cooperative 
Inner-City Asthma Study (NCICAS)[27], and the Inner-City Asthma Study[24, 28].  Questionnaires 
evaluating the child’s home environment, food allergies, eczema and rhinitis will be administered at 
baseline and at the end of each 48-week period. Standardized and validated tools for assessing 
outcomes will be utilized, such as the Composite Asthma Severity Index CASI)[29, 30].  
At the monthly injection visit, surveys are administered to ascertain symptoms, all wheezing 
episodes, and clinically significant wheezing episodes.   During the 96 week observation period, monthly 
phone calls will be conducted to ascertain symptoms and wheezing episodes and research clinic visits 
will be performed every 4 months.  
 
House Dust Sampling Environment Assessment: In addition to reported allergen and tobacco smoke 
exposure through frequent surveys, which provide reasonable markers for exposure, we will improve 
our precision[31-33]  with objective measures. Environmental home dust allergens will be collected at 
baseline, during treatment and observation periods, and measured using standard methods as 
published by the Boston group[34] and others[35]. All vacuum dust samples will be collected in a 
standard protocol[27] that avoids contamination through use of new, clean, disposable collector filters 
by the participant’s family or site staff and brought into clinic using a standardized and validated 
protocol[27] [34].  If the participant moves within the area, then one additional home sample will be 
collected in the same fashion.  Additional dust samples from baseline, end of treatment and end of 
observation will be banked appropriately, providing opportunities for future sequencing of the 
environmental microbiome, should funding become available.  
Study Visits and Assessments  
Screening Visit (Visit 0): Children 2-3 years of age with parental report or documentation of episodes of 
wheezing in the past year will be invited for a screening visit.  During this visit, we will obtain informed 
consent and further review inclusion and exclusion criteria.   
Children who fulfill screening criteria by survey and whose parents agree to participation will receive 
allergy skin testing to relevant aeroallergens, provide serum for total and specific IgE, and have height 
and weight measured.  Open-label albuterol metered dose inhaler (MDI) with AeroChamber® (Allergan, 
Dublin, Ireland) spacer and two courses of prednisolone/prednisone will be dispensed along with 
instructions on their use.  Parents will also receive a specific respiratory symptoms action plan/rescue 
algorithm and instructions on how to recognize onset of respiratory signs and symptoms, and the 
protocol for contacting study staff/physician. 
 
Run-In (2-10 Weeks between Screening Visit and Visit 1 Randomization): 
Participants who are on controller medications at enrollment must be stable off all controller 
medications for at least 4 weeks prior to randomization. Participants on ICS medications at a dose 
equivalent to PARK Step 2, 3 or 4 for more than 4 consecutive months at the time of enrollment will 
have their treatment decreased by one step every two weeks as described in Table 1. Participants who 
enroll on ICS will demonstrate at least a 4-week final run-in period to confirm stability off ICS prior to 
randomization.  Those who are not on any controllers at enrollment will have a 2-week run-in. The 
length of the run-in will be two-to-ten weeks depending on controller medication usage, duration of use 
and step level of ICS treatment reported at the enrollment visit. 
 
When total and specific IgE results become available, subjects who demonstrated either a positive skin 
test or positive allergen specific IgE ≥ 0.35 kU/L to at least one aeroallergen AND who are still eligible 
based on concentration of total IgE and other inclusion/exclusion criteria as detailed in Table 1 will be 
invited to return to the clinic for the randomization visit (Visit 1).   
Randomization and Treatment Phase Visits (Years 1 and 2; Visits 1-25):  
Children between the ages of 24 and 48 months who satisfy the eligibility criteria during the run-in 
period for being at risk for the development of asthma will be randomized to omalizumab (anti-IgE) or 
its placebo, with clinical center, age (2-<3 years vs ≥3 years at randomization), total IgE (≤100 IU/mL and 
>100 IU/mL), and gender as stratifying variables, and using the adaptive randomization approach of Hu 
et al[36] to minimize treatment imbalance across strata.   Roughly speaking, covariate adaptive 
randomization seeks to reduce treatment arm imbalance, with respect to important covariates, by altering 
the randomization probability when imbalance is detected. Unlike commonly employed block 
randomization, which reduces imbalance in a deterministic fashion by forcing at least one subject per 
block into the treatment arm that has fewer subjects, the covariate adaptive method preserves 
randomization for every subject, although not always 50:50.  Also unlike block randomization, which 
focuses on imbalance at the stratum level alone, covariate adaptive randomization also reacts to 
imbalances at the factor margin level and at the overall level.  The stratum level corresponds to the full 
cross classification of the stratification factors, in this case age, gender, IgE and clinical center.  The factor 
margin level corresponds to each factor individually, for example, balance across males and females 
irrespective of the other factors.  Overall level corresponds to the overall number of subjects assigned to 
each treatment arm irrespective of all factors. Covariate adaptive randomization is achieved by calculating 
imbalance, the difference in the number of subjects currently assigned to each treatment arm, at each 
level (stratum, factor margin, and overall) and then summing those differences in a weighted fashion. 
When imbalance is present, treatment arm assignment for the next subject uses unequal randomization 
probabilities, also called biasing probabilities, in order to increase the chances that imbalance will be 
reduced. When imbalance is not present, treatment arm assignment for the next subject uses equal 
randomization probabilities.  For the PARK study, we wished to avoid treatment arm imbalance on four 
different factors simultaneously (age, gender, IgE, and center) so that blocked randomization would have 
been impractical because there are 96 total strata (2 x 2 x 2 x 12).  However, this is an ideal setting for 
covariate adaptive randomization.  We chose to employ biasing probabilities of 0.15 and 0.85, along with 
a weighting scheme that gave equal weight (1/3 each) to imbalance at the strata level, at the factor 
margin level, and at the overall level.  Our choice of biasing probabilities and weights was driven by 
suggestions in the adaptive randomization literature. We performed a simulation study to demonstrate 
that the scheme would prevent gross imbalances with high probability, but we did not investigate the 
performance characteristics of different biasing probabilities or weights. 
Epinephrine auto injectors (Auvi-Q®, Kaleo inc., Richmond, VA, USA) 0.1 mg <15 kg, 0.15 mg 15-
30 kg and 0.3 mg >30 kg) and education on their use will be provided to the families as a precautionary 
measure in the rare event of delayed anaphylaxis.  The day after each investigational product 
administration, the parents will be contacted by telephone or e-mail/text (parent preference) to inquire 
about adverse events.  If any problems are noted via e-mail or text, a phone call will take place to gather 
the details of adverse events and to ensure that the child has received any necessary treatment.  
Dosing:  Dosing was carefully considered for this age range which has not been extensively 
studies previously.  Randomization of eligible participants was to subcutaneous omalizumab or placebo 
(1:1 randomization allocation ratio) every 4 weeks ensuring at least 0.016 mg/ kg/IU total IgE (measured 
at screening) in 75 mg increments utilizing pre-filled  75 mg and 150 mg syringes (PFS) with a maximum 
dose of 25 mg/kg. The dosing utilized was established in studies for the treatment of asthma in older 
children and adults and is described in the FDA approved package insert.  The maximum dose is 10% of 
the dose at which thrombocytopenia was seen in non-human primates. The dosing interval was limited 
to every 4 weeks to improve acceptability for caregivers and participants. The use of a dosing algorithm 
will allow the widest range of children to be covered.  Using this plan, we anticipated being able to provide 
sufficient omalizumab coverage to adequately dose 86% of children who would have met eligibility criteria 
based on data from the Childhood Asthma Research and Education (CARE) Network and The Urban 
Environment and Childhood Asthma (URECA)[35] cohort.  We plotted weight and IgE levels in our cohort 
studies to determine the percentage of children eligible for dosing based on our criteria. Using data from the 
CARE network and URECA on similar aged children with similar risk factors, we projected that most children 
would start and remain on one injection every 4 weeks during the treatment phase.    Depending on the 
patient’s body weight and serum total IgE at the screening visit, the dose will vary between75 mg and 
600 mg every 4 weeks.   
The dosing of each subject is determined by computer algorithm using information on current 
weight and enrollment total IgE gathered from electronic case report forms. The computer algorithm 
will allow the investigators to estimate the number of shots the child will receive at the visits over the 
course of treatment, based on the child’s weight percentile from CDC growth charts, and provide this 
estimate to parents prior to randomization.  In the package insert, adjustments for weight are 
recommended in the treatment of asthma, although no specific interval for such adjustment is given.   
During the 24-month treatment phase, children in this study would be expected to reach 127% to 138% 
of their enrollment weight.   Doses will be adjusted every 24 weeks at Study Weeks 24, 48 and 72.  Dose 
adjustments will be based on the most recent body weight measured in the clinic at one of the two preceding 
monthly visits.  
 
 
Observation Phase (Years 3 and 4; Visits 25-32):  
Participants will return to the research site every four months for clinical assessments and management 
of respiratory symptoms. Beginning at Week 100, participants will be contacted by phone each month, 
except when the calls would coincide with a clinic visit.  The occurrence of respiratory symptoms and 
medication use will be obtained.  The management of respiratory symptoms will also be conducted as 
described in a subsequent section. If indicated, a participant will be brought into clinic for an 
unscheduled visit. 
Table 2. Schedule of Events 
   
Treatment Phase (96 weeks) 
 
Treatment Phase (24 months) 








































































































 V2 V5 V9 V133 V17 V 1 V243 V25 
Run In +1               
 Informed Consent +                
Medical History +                
Physical Exam Heart/Lungs/Skin/ENT +     T24   +   T 72    + 
                                                          
 
   
Treatment Phase (96 weeks) 
 
Treatment Phase (24 months) 








































































































 Stadiometry and Weight5 +    + T20  T4 , 44  + T68   + + 
Inhaler Technique Assessment4 + +       +      +  
Blood Collection:                 
Specific/total IgE  +                
Free IgE         +      +  
Safety Labs -   CBC with differential 
and platelets, eosinophil count 
+   T8     +      +  
Blood for Mechanistic Studies +        +      +  
 
Allergy Skin Prick Test 
+ 
               
SQ Study Drug Administered2  + + + + + + + + + + + + + +  
Study Drug Dose Determination  +    T24   +   T72     
Medical Management of Respiratory 
Symptoms  
 
 + + + + + + + + + + + + + + + 
 
Spirometry/ Oscillometry Train  
            + +  + + 
Spirometry               + + 
Post-Bronchodilator Spirometry 
(post 4 puffs albuterol) 
              +  
 
Oscillometry (if available) 
               + + 
 
CASI 
+ + + + + + + + + + + + + + + + 
Questionnaires: 
ICAC/ISAAC/Home/Food 
 +       +      +  
Respiratory Action Plan Reviewed + + + + + + + + + + + + + + + + 
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Physical Exam Heart/Lungs/Skin/ENT    +   + 
Stadiometry and Weight + + + + + + + 
Inhaler Technique Assessment2    +   + 




 +   + 
 
Allergy Skin Prick Test 
      + 
Medical Management of Respiratory 
Symptoms 4 
 
+ + + + + + + 
 
Spirometry/Oscillometry Train  
+ + + + + + + 
Spirometry + + + + + + + 
Post-Bronchodilator Spirometry 
(post 4 puffs albuterol) 
   +   + 
 
Oscillometry (if available) 
+ + + + + + + 
 
CASI 
+ + + + + + + 
Questionnaires: 
ICAC/ISAAC/Home/Food 
   +   + 
Respiratory Action Plan Reviewed + + + + + +  
Study Management of Respiratory Symptoms 
During the entire study, respiratory medications will be managed according to an algorithm based on 
the National Asthma Education and Prevention Program expert panel report 3(NAEPP EPR-3) guidelines 
for the diagnosis and management of asthma. 
 
Because PARK will enroll children 2-3 years of age, we expect that nearly all subjects will experience at 
least one respiratory tract illness (RTI) during the course of this trial given the high prevalence of RTIs in 
this age group. While many of these RTIs will be limited to the upper airways, some RTIs may involve the 
lower airways and may therefore trigger or worsen respiratory symptoms in affected subjects[37]. A 
rescue algorithm will be implemented which is similar to the approach used in the Prevention of Early 
Asthma in Kids PEAK trial[26], AsthmaNet preschool studies [38] and in the Inner City Asthma 
Consortium. 
Each subject enrolled in this study will receive a respiratory symptoms action plan (PARK ACTION PLAN) 
outlining important triggers for starting treatment, including wheeze, increased work of breathing, or 
persistent disruptive cough.  
Parents will be asked to contact the PARK Center as follows: 
1. To inform them of worsening or persistent respiratory symptoms, or 
2. If respiratory symptoms do not improve after prednisolone/prednisone treatment, or 
3. After any unscheduled visit for respiratory symptoms, to either a primary care physician, sub-
specialty physician, urgent care facility, or emergency department, or 
4. After hospitalization for any reason, or 
5. Whenever they have specific questions or concerns. 
Parents will also be instructed by study staff, and directed by a respiratory symptoms action plan, to 
seek care immediately (e.g., urgent care or emergency department) for any symptoms requiring 
immediate medical attention, such as severe respiratory distress or rapidly progressive symptoms.  
Parents will be instructed to call the investigative site to inform the study personnel that emergency 
care was sought, after the child’s status has improved.   
We will also assess criteria that indicate the need for immediate medical attention at all study visits and 
direct the family to seek emergency care if not already obtained. 
 
 
Protocol for prednisolone/prednisone initiation for acute symptoms 
Parents will be instructed to call the investigative site or the on-call study clinician if, according to the 
PARK respiratory symptoms action plan, they have followed instructions and believe that further 
treatment is indicated for the treatment of their child’s respiratory symptoms.  
Information will be obtained from the phone call to ascertain whether any one of the following 
situations exist:  
A) Albuterol has been needed by inhaler/spacer or by nebulization for six or more individual 
treatments in the past 24 hours   
B) Symptoms of wheezing, shortness of breath, or tightness in the chest or cough or severe pain 
that do not significantly improve after 3 or more doses of albuterol administered every 20 
minutes over a period of 1 hour  
C) wheezing, or tightness in the chest, or cough, pain, or shortness of breath, plus associated 
activity limitations with or without albuterol occurs for at least 5 of the preceding 7 days. 
Parents will be instructed to initiate administration of the study-provided prednisolone/prednisone 
course only after the information obtained from the parent is reviewed by a study clinician. The 
prednisolone/prednisone course will consist of a 4-day course of oral prednisolone/prednisone: 2 
mg/kg/day for 2 days (maximum 60 mg/day), followed by 1 mg/kg/day for 2 days (maximum 30 
mg/day).    
Follow-up of prescribed prednisolone/prednisone burst 
If prednisolone/prednisone is recommended by PARK Clinical Center medical personnel, these personnel 
will telephone the parents 3-5 days after the initiation of the prednisolone/prednisone to reassess the 
child’s condition and determine whether an extension of prednisolone/prednisone courses may be 
warranted.   
If the child is still symptomatic during the 3-5 days phone call and the PARK Clinical Center medical 
personnel are comfortable with telephone management of the child (based on their medical judgment), 
the prednisolone/prednisone course will be repeated (i.e., 2 mg/kg/day for 2 days [maximum 60 
mg/day], followed by 1 mg/kg/day for 2 days [maximum 30 mg/day]). The study physician will make 
decisions on an extended course of therapy based on the child’s clinical response to rescue therapy or if 
symptoms worsen, determine whether the child should be assessed in the clinical center or referred to 
urgent care or the emergency department for additional evaluation.  
Management of Controller Medications for Persistent Symptomology 
Controller therapy will be provided by the study and will be initiated when one of three conditions is 
met: 
A. Persistent symptoms*, as described below, for at least 2 weeks after a 4-8 day corticosteroid 
burst 
B. Two or more  symptomatic wheezing episodes that require a corticosteroid burst in a six-month 
period 
C. Need for a hospitalization for a symptomatic wheezing episode since the last assessment. 
* Symptoms include – 
a) daytime wheezing, chest tightness, or cough which occurs nine or more days in the past 2 
weeks and causes at least minor activity limitation, or 
b) nighttime symptoms of wheezing, chest tightness, or cough that disrupt sleep occurring at 
least three nights in the past 2 weeks, or  
c) SABA use for symptom control (not prevention of exercise induced bronchospasm) nine or 
more days in the past two weeks. 
Once the child meets criteria for the initiation of controller therapy, the child will be started on Step 1 
therapy and adjusted as indicated (see Table 3.  Medication Regimens).   
Table 3. Medication Regimens 
Step Medication Equivalents 
0 SABA only 
1 Fluticasone (Flovent®) MDI HFA 44 mcg/inh (1p BID) 
2 Fluticasone (Flovent®) MDI HFA 44 mcg/inh (2p BID) 
3 Fluticasone (Flovent®) MDI HFA 110 mcg/inh (2 puffs bid) 
4 
Fluticasone (Flovent®) MDI HFA 110 mcg/inh (2 puffs bid) plus 
Montelukast (Singulair®) 4mg po qd for 2- 5 year olds 
Montelukast (Singulair®) 5mg po qd for 6 years old and above 
5 
Fluticasone propionate and salmeterol 115/21 (Advair HFA) at 2 
inhalations bid 
6 
Fluticasone propionate and salmeterol 230/21 (Advair HFA) at 2 
inhalations bid 
 
Adjustment of therapy after controller medication initiated 
To accommodate for variation in the course of recurrent wheeze and preschooler respiratory symptoms, 
the protocol has established criteria for increasing and tapering asthma controller medications based on 
clinical symptoms and NAEPP EPR-3 guidelines [39].   
Each month, the clinician will use information obtained via study questionnaires to determine the 
highest “symptom level” of the participant’s morbidity described in Table 4- Determination of Symptom 
Level. During the treatment phase, the assessment will be made at each scheduled clinic visit.  During 
the observation phase, the questionnaire will be completed by telephone every month, except when a 
clinic visit is scheduled which will allow for completion at the study site.  Additionally, evaluation of a 
subject’s respiratory status can be performed at an unscheduled clinic visit.  
At the time of each assessment, the study clinician’s decision to increase, decrease or keep same the 
controller medication is determined by applying the participant’s “symptom level” to the treatment 
algorithm (Table 5– Treatment Algorithm).  Adherence to the prescribed controller regimen further 
directs the treatment algorithm and will be obtained preferably from the medication counters, but per 
verbal report, if necessary.  
Based on the Treatment Algorithm, the clinician then selects the appropriate treatment step (Table 3 
Medication Regimens). The medication step level may be increased on a monthly basis as indicated by 
symptoms.  Medication step levels cannot be decreased after a step level increase until a participant has 
been stable for at least 6 weeks; generally this will be two consecutive monthly assessments using 2-
week recall, unless there is a 6 week duration between when the step level was increased and the 






Table 4 - Determination of Symptom Level (2-week recall for symptoms and activity limitation)  
Symptom 
Level 
# days with 
wheezing, or 
tightness in the 
chest or cough / 
two weeks and 
at least minimal 
limitation of 
activity 











the chest or 
cough / two 
weeks  
# nights use of 

















>5 >5 >2 nights >2 nights ≥1 
 
Table 5 Controller Medication Treatment Algorithm (Applied only to subjects currently taking 
controller medications) 
Symptom Level 
(from Table 4) 
Treatment Algorithm for Participants with 
Acceptable Adherence (≥50% of prescribed 
controller doses taken) 
Treatment Algorithm for 
Participants with Unacceptable 
Adherence (< 50% of prescribed 




If participant has been on their current Step 
(1-6) for <6 weeks – no change in treatment  
If participant has been on their current Step 
(1-6) for ≥6 weeks – decrease treatment by 
one step unless the participant has taken 
prednisolone for respiratory symptoms 
within the previous 28 days. 
Assess acute symptoms for initiation of 
prednisone  
If participant has been on their 
current Step (1-6) for <6 weeks – no 
change in treatment  
If participant has been on their 
current Step (1-6) for ≥6 weeks – 
decrease treatment by one step 
unless the participant has taken 
prednisolone for respiratory 
symptoms within the previous 28 
days. 
Assess acute symptoms for initiation 
of prednisone  
Symptom Level 
(from Table 4) 
Treatment Algorithm for Participants with 
Acceptable Adherence (≥50% of prescribed 
controller doses taken) 
Treatment Algorithm for 
Participants with Unacceptable 
Adherence (< 50% of prescribed 





If currently on Steps 1-5, increase controller 
regimen by 1 Step or, 
If currently on Step 6, continue Step 6  
Assess acute symptoms for initiation of 
prednisone  
Continue same controller regimen or 
place on Step 2 therapy, whichever is 
higher 
Assess acute symptoms for initiation 
of prednisone  
 
TREATMENT FAILURE 
A participant will be considered a treatment failure and will be treated per physician discretion if any of 
the following criteria are met: 1) a participant requires 2 hospitalizations extending across more than 
one night per hospitalization for wheezing or asthma in a 12 month period, 2) requires intubation for 
acute wheezing or asthma exacerbation at any time, 3) has a hypoxic seizure during a wheezing or 
asthma exacerbation at any time, or 4) has more than 4 systemic steroid treatments for wheezing or 
asthma exacerbations within a 12 month period.  If a treatment failure occurs then study drug will be 
stopped, but the child will continue to be followed in the study to evaluate long term safety and 
outcomes and to facilitate clinical care in concert with the participant’s primary care or specialist 
provider. 
Primary Outcomes:  There are two primary outcomes: a predefined asthma outcome based on the 
NIAID funded URECA cohort[35] and asthma severity in the children who develop asthma assessed by 
the CASI[40].  The analysis plan for our proposed hypothesis of the two primary outcomes of asthma 
prevention and reduction of asthma severity in those who do develop asthma is described in the 
statistics and analysis section.  
1. The diagnosis of current asthma at the end of the observation period. 
A. 1 or more hospitalizations for wheezing/ asthma, or 
B. 6 or more months of asthma controller use, or 
C. 2 or more wheezing episodes, or 
D. 2 or more Dr. or ED visits for asthma, or 
E. FEV1 reversibility > 10% after 4 puffs albuterol PLUS 
 1 or more wheezing episodes  
 1 or more physician or ED visits for wheezing/ asthma  
* A wheezing episode is defined as parental or documented report of an episode of wheezing or 
whistling in the chest that lasts at least 24 hours.  Wheezing events separated by at least 5 
consecutive days without wheezing shall be counted as separate episodes. 
 
2. Average CASI score over the final three clinic study visits with the score set to zero for children 
without diagnosis of current asthma. 
 
Secondary outcomes: 
1. Number of wheezing episodes analyzed in each consecutive 48 week period (treatment and 
observation phases)   
2. Number of clinically significant wheezing episodes analyzed in each consecutive 48 week 
period (treatment and observation phases)  
3. Development of sensitization to new allergens as measured by in vitro (ImmunoCAP) and in-
vivo (skin testing) assessment of allergen-specific IgE at the end of the observation period 
Safety outcomes: 
1. Number of adverse events will be analyzed by the frequency of adverse events  
Exploratory Outcomes: 
Exploratory outcomes to be analyzed separately in both the treatment (96 weeks) and observation (96 
weeks) periods (unless otherwise limited) will include: 
 
1. Time to first wheezing episode or clinically significant wheezing episode during the 
intervention and observation period 
2. Lung function (FEV1, FEV1/FVC, FEF25-75, bronchodilator responsiveness (% change in FEV1 
post albuterol))[41] at 92 weeks and during the observation period 
3. Asthma-like symptom days in the past 2 weeks as modeled in the Inner-City Asthma 
Consortium defined as the largest value among three variables: number of days with 
wheezing, tightness in the chest or cough, number of nights with disturbed sleep as a result 
of asthma, and number of days on which the child had to slow down or discontinue play 
activities because of asthma[28] 
4. Number of systemic corticosteroid courses 
5. Time to first systemic corticosteroid course 
6. Medical/health care utilization (i.e. number of hospitalizations for wheezing during the 
intervention and observation periods and Number of ED and unscheduled medical visits for 
wheezing during the intervention and observation periods) 
7. Growth and BMI 
8. Proportion of participants with physician diagnosed atopic dermatitis, allergic rhinitis, 
asthma, or food allergy throughout the trial 
9. Proportion of participants with asthma primary outcome at the end of  the first 48 weeks of 
the observation phase of the trial 
10. Proportion of participants with atopic dermatitis defined as  doctor’s diagnosis of eczema 
and current symptoms of itchy rash in areas typical of eczema during the observation period 
11. Proportion of participants with allergic rhinitis (seasonal or perennial rhinitis by 
questionnaire, and corresponding allergen specific IgE by skin tests and/or allergen specific 
IgE). 
12. Number of food-induced allergic reactions in those participants who have physician 
diagnosed food allergy during the intervention and observation periodsAnalysis Plan 
Analysis Population 
For the 96-week observation extension, the enrollment target sample size is 250 participants, among 
whom we account for 20% dropout, giving an expected analysis sample of at least 200.  The projected 
attrition is based on other similar studies such as Prevention of Early Asthma in Kids Study (PEAK), which 
had 10% dropout. 
We will follow the intention-to-treat principle for the primary analysis, attributing the randomly 
assigned treatment to each subject regardless of adherence.  Thus, the available data from all 
randomized children will be included in the statistical analyses, regardless of treatment failure status.  
As secondary analyses we will compare outcomes according to level of adherence, and also conduct an 
alternative analysis in which data collected after the assignment of treatment failure status are 
excluded.   
A per protocol analysis will be performed in a similar manner to the intention-to-treat except the 
population analyzed will be those participants who receive at least 75% of injections, have missed 3 or 
fewer consecutive doses and have either completed visit 32 or have a phone interview in its place.  
The safety population will include all participants who are randomized and received at least one dose of 
the investigational product. 
Descriptive Analyses  
Descriptive statistics will be calculated for all baseline measurements and characteristics, continuous 
variables (means and standard deviations, or medians and inter-quartile ranges) and categorical 
variables (frequencies).  The descriptive statistics will be calculated based on the treatment arm 
allocation, in order to assess whether the two groups differ prior to the treatment period.  Given the 
target sample size for this trial of 250 randomized children, it is expected that the two groups will be 
balanced with respect to demographics and prognostic variables. 
Primary Analysis of Primary Outcomes   
The first primary clinical trial outcome is dichotomous:  diagnosis of current asthma during the final 48 
weeks of the follow-up period off therapy.  This will be assessed at the end of the trial since our 
definition includes diagnosis and symptoms/medication requirements in the past year.  We will compare 
the proportion of subjects with current asthma diagnosis between treatment arms using the chi-square 
test with significance level 0.04.  
The second primary clinical trial outcome, asthma burden, is semi-continuous: the CASI score averaged 
over the final 3 clinic study visits.  The CASI score is a measure of asthma severity that takes integer 
values between 0 and 20 inclusive so the average CASI score over the final 3 visits is also constrained by 
the limits 0 and 20.  Because the elements that comprise the CASI score are the same as those that 
determine asthma diagnosis: use of controller medication, severe wheezing episodes, hospitalization 
and lung function, the CASI score will necessarily be greater than zero for children diagnosed with 
asthma.  It is possible for a child who does not have asthma to have an observed non-zero CASI score 
due to the occurrence of “asthma-like symptoms”.   However, since we are interested in true asthma 
burden, not the occurrence of asthma-like symptoms, the asthma burden score will be zero for all 
children without asthma diagnosis, regardless of what their CASI score would have been had they been 
diagnosed with asthma.  We will compare the asthma burden score between treatment arms using the 
Wilcoxon test with significance level 0.01. 
Analytic approaches for Secondary, Mechanistic, and Exploratory Outcomes 
Secondary outcomes, listed above, include dichotomies, counts, time to event, and continuous 
measures.  Dichotomous outcomes will be analyzed by logistic regression.  Counts, typically small 
integers tabulated over a fixed period, will be analyzed by log-linear regression based on negative 
binomial likelihood, using covariates and effect modifiers as with the dichotomies and an offset to 
account for variable assessment periods.  Continuous outcomes determined at baseline and follow-up, 
including the primary mechanistic endpoint (T-cell proliferation assay), will be analyzed by factorial 
repeated measures analysis of variance (ANOVA) with time × treatment interaction as the featured 
hypothesis, assessing the between-arm difference in change between baseline and follow-up.  Skewed 
variables will be appropriately transformed for analysis.  Covariate adjustments and tests of 
heterogeneity of effect will be applied as with the dichotomies and count data.  Time-to-event 
outcomes will be compared between arms by Cox (proportional-hazards) regression, similarly to the 
above regression methods.  For outcomes determined at multiple intervals during the trial, we will also 
employ repeated-measures ANOVA to compare the entire time course of the endpoint between 
treatment arms, forming and testing pertinent contrasts at time points of interest from parameters of 
the fitted longitudinal model.  We will account for serial correlation in individuals’ measurements by use 
of a compound-symmetric or autoregressive covariance structure, as appropriate for the endpoint.  For 
the more frequently measured variables (e.g., growth) we will construct spline models, comparing the 
magnitude and placement of nonlinear features of the time course as well as the overall trend. 
Supportive Analyses of the Primary and Secondary Outcomes  
Supportive analyses of the primary outcomes will include further modeling approaches incorporating 
covariate adjustments and tests for interaction (effect modification, heterogeneity of effect).  The first 
primary outcome can be modeled using logistic regression.  Since the second primary outcome is a 
combination of binary and semi-continuous components, there is no natural location parameter to 
model.  We will follow the approach of Vermeulen et al and model the marginal probabilistic index, 
which is the probability that a randomly chosen subject from the omalizumab group has a lower 
outcome than a randomly chosen subject from the placebo group.[42]  In order to understand the 
treatment effect gradient, we will employ a pre-specified approach to assessing heterogeneous 
treatment effect, using baseline risk factors.[43] These will be assessed by interaction tests (covariate × 
treatment group).  Of particular interest is the question of risk × treatment interaction, which addresses 
the possibility that the treatment could be more efficacious for more severely affected participants.  A 
finding of significant heterogeneity in this regard would have important clinical implications.  Further 
analysis, if we make such a finding, could include testing individual domains of the primary outcome 
and/or secondary outcomes that have multiple domains, such as the individual components of the CASI, 
to determine whether particular components may be driving the heterogeneity of response. A strength 
of the proposed study is that we have access to external tools (CASI) comprising several domains, which 
can be applied straightforwardly for a test of interaction with treatment[44].  If the interaction is 
significant we can, as suggested by Wang and Ware[45], divide the risk scale into categories and provide 
category-specific estimates of treatment effect.  The same sort of analysis can be conducted with 
individual domain scores.  
 Also worth pursuing is development of an internal risk score, which has the advantage of prima facie 
pertinence to the study sample.  To carry out this alternative assessment of risk we will use the 
proportional-interaction model of Kovalchik[46] and Follman and Proschan[47].  Burke et al[48] 
obtained the best results using data from both arms to develop the internal multivariable score.  To 
avoid overfitting, they recommend having at least 10 control-arm events per predictor variable.  We 
project 50% will have diagnosis of current asthma in 100 placebo subjects, or 50 events; thus an internal 
tool would be limited to 5 predictors, not a severe constraint as CASI comprises only 5 domains, and 
other similar studies have even successfully employed a subset[49]. 
Exploratory analyses will also include examination of seasonal effects, allergen exposure concentrations, 
sensitization, and the combination of exposure + sensitization.  These analyses will again include 
interaction terms in models to determine of any of these factors predict responsiveness to the 
intervention.   
Missing Data 
We will follow recently published guidelines for the handling of missing data[50].  The potential 
influence of missing covariates will be evaluated by first comparing dropouts to completers with respect 
and baseline or, if available, more recent characteristics.  If no measured characteristics distinguish the 
groups, that constitutes evidence supporting the assumption that the missing data can be considered 
missing completely at random (MCAR), and the analysis methods described above can be relied on to 
produced valid estimates of treatment effect.  If the groups differ with respect to recorded covariates 
only (missing at random, MAR), then the missing covariates can be filled in by multiple imputation 
methods.  If the occurrence of missing values is not adequately explained by recorded variables, or the 
assumption of MAR is not adequately supportable (missing not at random, MNAR), we will assess the 
sensitivity of the results to hypothetical scenarios for biased dropout.  The potential influence of missing 
endpoints will be assessed by conducting an alternative inverse-probability-weighted analysis.  Weights 
are derived from a model of the full data in which the occurrence of a missing endpoint is the 
dependent variable (rather than the value itself), and all available covariates are predictors.  In addition, 
as noted above, lack of relationship between missingness and measured characteristics does not 
guarantee MCAR. Therefore, additional sensitivity analyses will be conducted by imputing the limiting 
cases for missing values under the null hypotheses (i.e., all missing values imputed as positive for 
asthma diagnosis or all missing values imputed as negative for asthma diagnosis). 
Statistical Hypotheses  
Our primary null hypotheses are:  
1. That a current diagnosis of asthma at the end of the final observation year (Year 4), following 
96 weeks' treatment of randomly assigned omalizumab or placebo and an intervening off-
treatment year, will be equally frequent among trial subjects in the two groups.  We will test 
this hypothesis with a two-sided test Type I error probability of 0.04 as described below.  The 
alternative hypothesis is thus that the current diagnosis of asthma is not equal in the two 
groups, allowing for the outcome to be more frequent either in the omalizumab group or in 
the placebo group. 
2. That the total asthma burden, combination of diagnosis and severity, at the end of the final 
observation year (Year 4), following 96 weeks' treatment of randomly assigned omalizumab or 
placebo and an intervening off-treatment year, will be equal among trial subjects in the two 
groups.  We will test this hypothesis with a two-sided Type I error probability of 0.01 as 
described below.  The alternative hypothesis is thus that the asthma burden is not equal in the 
two groups, allowing for the outcome to be higher in the omalizumab group or in the placebo 
group. 
The significance levels 0.04 for the prevention outcome and 0.01 for the burden outcome 
were chosen to ensure that the total familywise type I error rate for the two primary null 
hypothesis tests will not exceed 0.05.   In order to maximize the power for each test, decision 
rules for rejections will be based on the closure principle as shown below.  If either the 
prevention null hypothesis or the burden null hypothesis is rejected, then the trial will be 
considered successful in terms of demonstrating a treatment effect.  As a sensitivity analysis, 
we will repeat the primary analyses with p-values calculated using the permutation testing 
approach instead of the population sample likelihood approach.  
Table 6. Power  










< 0.04 < 0.01 YES YES YES 
0.04 – 0.05 < 0.01 YES YES YES 
> 0.05 < 0.01 NO YES YES 
< 0.04 0.01 – 0.05 YES YES YES 
0.04 – 0.05 0.01 – 0.05 NO NO NO 
> 0.05 0.01 – 0.05 NO NO NO 
< 0.04 > 0.05 YES NO YES 
0.04 – 0.05 > 0.05 NO NO NO 
> 0.05 > 0.05 NO NO NO 
 
For secondary and exploratory endpoints, our hypothesis is that the likelihood (for dichotomous 
endpoints), mean count (for countable endpoints), hazard (for time-to-event endpoints), mean value 
(for continuous endpoints), or time course (for repeated measures) is equal in the two treatment 
groups, with a two-sided alternative.  We will use Type I error 0.05 as the criterion for statistical 
significance without adjustment for multiple testing, following the rationale of Glantz and Slinker[51] by 
which each of the above planned comparisons represents a separate hypothesis of scientific interest.   
We will use a more stringent criterion for exploratory hypotheses and apply formal methods such as the 
Holm step-down procedure[52] only in cases of pre-planned multiple testing, such as comparing levels 
of a multi-category predictor or assessing multiple simultaneously assayed markers.  In those cases we 
will apply a familywise Type I error rate 0.05 and calculate the False Discovery Rate at each step by the 
method of Benjamini and Yekutieli[53]. 
Our calculations of detectable effect (below) uniformly assume power 0.9 (Type II error 0.1), reflecting a 
conviction that a study of this scale should provide low chance of failing to demonstrate clinically or 
biologically significant treatment effects whenever such effects are present. 
SAS software (version 9.4 et seq.) and R will be used for statistical computations. 
 Sample Size Considerations  
For the following calculations we set the Type I error rate (0.04, 0.01, or 0.05 as described above) and 
determined the magnitude of effect detectable with power 0.9 (Type II error 0.1), given our anticipated 
sample size (allowing conservatively for 20% attrition).  We can thus argue that the study is adequately 
powered to demonstrate effects as small as those described here, covering the clinically or biologically 
significant range and justifying the large-scale effort that the study entails. 
 Clinical Trial.  
 Our sample of 250, allocated 1:1 (omalizumab: placebo) and allowing conservatively for 20% dropout, 
gives us 100 treated patients and 100 controls to compare.   
 With respect to the prevention null hypothesis:  If the risk of current asthma diagnosis is 0.50 in 
the placebo group, we will have power of at least 0.9 to detect an absolute risk decrease of 0.23 
for omalizumab compared to placebo.  This corresponds to a relative risk of 0.54 for 
omalizumab compared to placebo.  The assumption for placebo is based on unpublished data 
from the NIAID URECA birth cohort, in which children who fulfilled the PARK inclusion/exclusion 
criteria at age 2-3 years of age demonstrated a 50% risk of developing asthma as defined by 
URECA at age 6-7.  Assuming the known treatment effects of anti-IgE in school aged children 
(50-80% reductions in exacerbation rates)[24, 54]  in comparison with the observed risk of 
current asthma diagnosis at age 6-7 in URECA, we are being appropriately conservative in our 
powered effect size.  Furthermore, we conducted a sensitivity analysis of a range of effects 
based on treatment effects of other therapies in the PARK age range and their observed 
outcomes in the placebo arms (see section below). 
 With respect to the burden null hypothesis:  If the risk of current asthma diagnosis is 0.50 in the 
placebo group and the absolute risk decrease for omalizumab compared to placebo is 0.23, and 
if the average CASI score for those with asthma diagnosis in the placebo group is 3.5 and the 
average CASI score for those with asthma diagnosis in the omalizumab group is 2.7, then we will 
have will have power of at least 0.9  to detect a decrease in asthma burden for omalizumab 
compared to placebo.  This corresponds to an absolute decrease of 0.8 in the average CASI score 
for those with asthma diagnosis, which is slightly smaller than the published Minimally 
Important Difference of 0.9.  As noted above, the prevention null hypothesis is independent of 
any changes in severity among those with asthma diagnosis, whereas the burden null hypothesis 
depends on changes in both asthma risk and severity. Thus, it is possible to achieve high power 
for the burden outcome even if there is very little prevention effect as illustrated in the figures 
below.  Although the maximum CASI score is 20, that value represents very severe asthma (daily 
symptoms, more than 3 nighttime awakenings per week, lung function less than 70% of 
predicted, high-dose ICS controller therapy, and recent hospitalization).  We anticipate relatively 
low CASI scores in the PARK study.  We assumed a mean CASI score of 3.4 in the placebo group, 
which corresponds, for example, to low-dose ICS controller therapy with lung function greater 
than 85% of predicted, symptoms 3 days per week and one nighttime awakening per week.  For 
the purposes of power calculations, we assumed that the CASI scores followed a negative 
binomial distribution with mean 3.4 and variance 3.6, which has a 95
th
 percentile of 7.  So 
although the negative binomial would theoretically have to be truncated at 20, our assumptions 
entail a very low likelihood of CASI scores greater than 10.  The Inner City Asthma Consortium, 
which developed the CASI score, suggested an MID of 0.9 with Hedges g statistic of 0.36 (JACI 
2017).  Our target effect size is 0.8 for power 0.9. 
 With respect to secondary and exploratory outcomes:  These can be grouped in the following 
four classes:  dichotomous conditions assessed at the end of follow-up; count data measured in 
a fixed period; time-to-event endpoints; and measured variables, assessed in both groups at 
baseline and the end of the trial (including T-cell proliferation, the main mechanistic endpoint).   
o Dichotomous outcomes: The expected proportions drive the power calculation.  For 
outcomes with relatively low expected proportions, such as 0.3, our sample size is 
adequate to detect a risk decrease of 65% (relative risk 0.35), but for outcomes with 
higher expected proportions, such as 0.7, our sample size is adequate to detect a risk 
decrease of only 35% (relative risk 0.65). 
o Count data outcomes: The expected rates drive the power calculation.  For outcomes 
with a relatively low rate, such as 1.0, our sample size is adequate to detect a rate 
decrease of 50%, but for outcomes with a higher rate, such as 4.0, our sample size is 
adequate to detect a rate decrease of only 25%. 
o Time to event outcomes:  The expected numbers of events drive the power calculation.  
For relatively uncommon events, our sample size is adequate only to detect several-fold 
relative hazard; but for a more common event, likely to occur in about half the sample, a 
more modest effect size, around two-fold, will be demonstrable. 
o Continuous outcomes:  The standard deviation of individuals' pre-post change is 
SDΔ=SD×(2(1–ρ))1/2, where ρ is pre-post correlation.  For (approximately) Gaussian 
distributed outcomes, the detectable difference in mean change between treatment 
groups lies between 0.38 and 0.58 SD, depending on pre-post correlation.  These 
differences correspond to a shift in distribution, such that the mean in one group aligns 
roughly with the upper tertile boundary in the other group (percentile 64-72).  This is a 
relatively small but potentially clinically significant shift, as one-sixth of the shifted 
group are newly located above the median of the other group.  For outcomes that 
require a logarithmic transformation, detectable effect sizes are shown relative to the 
coefficient of variation (given as percentage). 
 
Sensitivity analysis 
The power of this study design to detect smaller or larger treatment effects for the first primary 
outcome was investigated across a range of risks in the placebo group as shown in the figure below. The 
target sample size of 250, with 20% attrition, will provide power of at least 0.79 for the targeted effect 
size even if the risk in the placebo group is as low as 0.40 (20% smaller than expected), and power at 
least 0.70 of the targeted placebo risk even if the relative risk is as high as 0.64 (20% smaller treatment 
effect than expected).  
 
Figure 1.  
Our assumptions are appropriately conservative by targeting a population at most risk for persistent, 
progressive disease that will also be directly targeted by our intervention.  This allows us to focus on a 
population most likely to respond to the therapy but not so far along with established asthma that 
modification of progression or prevention will be less precise to detect.  
The figure below illustrates the effect of asthma burden effect under different asthma prevention 
scenarios.  If the true omalizumab relative risk is 0.54, the value on which the prevention outcome 
power is based, then the burden outcome power is high regardless of whether omalizumab affects the 
CASI score.  If the true omalizumab prevention effect is weaker, for example relative risk is 0.65 (in 
which case the power for the prevention outcome is only 0.7), the power for the burden effect can still 
be adequate if omalizumab has an important effect on the CASI score.  The overall probability of a 
successful trial (either or both null hypothesis rejected) is at least as high as the higher of the pertinent 
curves in the two panels below.  For example, if the omalizumab prevention effect relative risk is 0.65 
and the CASI effect is 1.0, then the overall probability of a successful trial is at least 0.80. 
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Figure 2  
DISCUSSION 
The PARK study is a unique intervention trial targeting IgE, the central antibody related to 
allergic sensitization and recently implicated in innate viral response, to determine if asthma can be 
prevented or the severity modified in young children at high risk of the developing the disease. PARK 
brings together a team of established childhood asthma investigators to design and implement the 
intervention trial that is challenged by maintaining scientific rigor while achieving feasibility of recruiting 
young children to receive serial injections in a placebo controlled trial. Even prior to starting the clinical 
trial, It took over a decade of working with the Food and Drug Administration and amassing real world 
omalizumab safety data for nearly two decades before an Investigational New Drug (IND) was granted 
down to age 2 years.   
Our study is focused on prevention. The ability to assess this endpoint involved establishing eligibility 
criteria that met  FDA requirements on treating a group of children at high enough risk to justify such a 
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treatment who did not already have established persistent asthma.  We acknowledge the population 
treated within these constraints may limit the generalizability of our results. However, this will provide 
important insight into the role of early immunomodulation by treatment with omalizumab in such a 
population and leverage our understanding for further study.   
Since starting this trial, there have been several lessons learned. Prevention studies in young 
children face unique challenges to enrollment compared to many other clinical trials. Prevention studies 
require the prospective participant’s parents and caregivers to do a more complex and less concrete 
weighing of potential risk versus potential benefit over the long term as opposed to trials addressing an 
established need, potential for immediate symptom relief, and often shorter period of involvement for a 
pre-existing disease. Add to that the young age of the children and parenteral treatment, the decision 
faced by a parent or guardian is difficult.  To date, the majority of participants have been recruited from 
the allergy/asthma specialty clinics and frequently have other allergic conditions. Family history of 
severe disease in the parents or older siblings is also a motivating factor.    The most successful 
recruiters have been strong physician advocates.  A physician champion in clinic who could clearly and 
confidently explain the rationale and goals behind the study is by far the most effective recruiting tool 
and this approach works well for most clinical trials since it is important for families to have an 
explanation for the study from someone who understands the treatment.  Such enthusiasm might 
increase a placebo effect in shorter trials but we think it unlikely to have a substantial effect in a trial of 
this duration.  Additionally, the protocolized asthma treatment algorithm should limit the placebo effect 
on outcome.    
 
Online recruitment tools have also been helpful. We have added a multi-center website 
(https://parkstudy.org/) explaining in simple terms the study with tabs by location for interested 
participants to enter to obtain more information.  Facebook and other awareness strategies are being 
used and a simple  blog https://vector.childrenshospital.org/2016/08/asthma-prevention-xolair/ made 
by the Boston Children’s Hospital has been  effective in increasing interest.  
 Once interested in participating, talented staff foster trusting relationships with the families and 
maximize sustained involvement.   In our centers with a Spanish speaking populations, we adapted study 
materials, including the electronic CRFs, to Spanish and our committed, multi-lingual, cross-cultural 
study staff have been creative in ways to implement strategies for translation when bilingual staff and 
physicians were not available[35, 55].    
Performing serial injections in a young child for clinical research can be traumatizing. To decrease 
discomfort and fear of the monthly injections, we’ve offered multiple strategies including numbing 
cream and  Buzzy® (Pain care Labs inc., Atlanta GA, USA) distractors.   
The protocol has needed modification as practice pattersn have changed.  The focus is prevention 
and yet appreciable risk is required to justify the intervention, so, initially a “window of opportunity” 
was set requiring children to have 2 or 3 wheezing episodes but excluding those on > 4months of 
inhaled corticosteroids in the past year. Given the early use of daily inhaled corticosteroid 
recommended under current guidelines[56] , the restriction to 4 months of ICS impaired our ability to 
recruit and excluded children who might benefit the most from this approach. The current widespread 
ICS use does not necessarily identify patients who have asthma and the increase in the use of ICS in 
young children during a time of decreased incidence of asthma suggests that some of these children are 
overprescribed this type of therapy[57, 58].  Finally, it has been noted that in children aged 1- 4 years, 
wheezing phenotypes are often unstable.  As an example, multi-trigger wheeze, often considered a 
surrogate for an asthma diagnosis in pre-schoolers, and episodic viral wheeze are not stable 
phenotypes, with 32% of children changing phenotype over time[59].  In support of this, the 
Individualized Therapy for Asthma in Toddlers (INFANT) trial enrolled children on EPR-3 Step 2 guideline 
therapy for one year of treatment.  The children were symptomatic at baseline (required an average of 2 
oral corticosteroid courses in the 6 months prior to enrollment, and had an average of 5 wheezing 
episodes prior to study entry, with 15% hospitalized for wheezing) yet during the trial 1/3 of these 
children  had very low rates of  symptoms throughout the study (mean asthma control days above 95% 
during all treatment periods) [60].  This suggests that if we exclude such patients symptomatic to the 
point of needing step 2 therapy at baseline, we likely will exclude children without stable asthma who 
might benefit from the trial.  For these reasons, we approached the FDA to modify the ICS exclusion 
criterion and were allowed to change the protocol as presented with the addition of protocolized 
monitoring to safely wean children currently using ICS >4 months (excluding children on step 5 or 6 at 
enrollment) and give them the opportunity to demonstrate stability off medications prior to enrollment.   
In early 2020 the COVID-19 pandemic caused new safety challenges and suspension of 
enrollment. The focus shifted to providing therapy to children already randomized and obtaining safety 
labs.  The pandemic and its attendant changes in standards for patient contact limited our ability to do 
some procedures and sampling.  We worked to maximize remote participation. The FDA cleared and the 
IRB subsequently allowed us to offer home drug administration during the pandemic as long as 1) the 
child had no prior history of anaphylaxis; 2) at least 3 doses of omalizumab had been given in clinic; 3) 
training was provided to the parent/caregiver to recognize and manage signs and symptoms of a severe 
hypersensitivity reaction, including anaphylaxis, and 4) parent/caregiver was confirmed to be able to 
perform injections with omalizumab PFS with proper technique, based on the guidelines of Genentech 
and the FDA advisory due to the pandemic[61, 62]. We also added provisions for remote monitoring 
during injection.  Delivering omalizumab or placebo to a family was a challenge due to temperature 
control requirements, and we provided an option for drive through pick up or courier service. As of this 
writing, we were able to continue to provide injections for most of the participants during the pandemic 
with in-person visits as first choice.  Given the extra challenges and logistics in doing home injection, this 
is reserved as a final resort for families who simply will not come to the research clinic during the 
pandemic.   
PARK is a potentially paradigm-shifting study.  The trial’s innovation focuses upon early life 
intervention to modify the development and progression to disease during a critical time in lung growth 
and immune development, and relies on evidence that omalizumab completely blocks the effects of  
IgE-allergen interactions that 1) critically regulate progression to persistent asthma in susceptible 
individuals, 2) contribute to susceptibility to virally-induced exacerbations—both of which are 
fundamental in progression to established disease.   If successful, omalizumab (anti-IgE) therapy will be 
the first intervention to significantly alter the progression from wheeze to established pediatric asthma.  
It will have tremendous impact on pharmacotherapeutic development and basic/translational 
approaches to asthma.  If positive, the results could strengthen rationale for IgE targeted interventions 
by not only antibody-based mechanisms but further development of small molecule therapeutics, which 
are currently in the early stages of development.    No matter what our results, the outcomes of this trial 
will provide significant insights into the pathobiology of asthma and potentially other IgE-mediated 
allergic diseases (i.e. food allergy and allergic rhinitis), and prepare us and others to identify the next 
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